We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00168441
First Posted: September 15, 2005
Last Update Posted: May 30, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Allergan
September 12, 2005
September 15, 2005
May 30, 2011
June 2004
June 2005   (Final data collection date for primary outcome measure)
Pain score
Same as current
Complete list of historical versions of study NCT00168441 on ClinicalTrials.gov Archive Site
  • Various Quality of Life questionnaires
  • Reduction in area of pain/allodynia
Same as current
Not Provided
Not Provided
 
A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia
Not Provided
4-month study including a 30-day baseline phase
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Postherpetic Neuralgia
Drug: Botulinum Toxin Type A
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
117
June 2005
June 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion Criteria:

  • Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00168441
191622-066
Not Provided
Not Provided
Not Provided
Therapeutic Area Head, Allergan, Inc
Allergan
Not Provided
Not Provided
Allergan
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP